A new clinical trial for a Hepatitis B treatment has demonstrated promising results, with approximately 20 percent of patients achieving a functional cure. A functional cure occurs when the hepatitis B virus surface antigen and viral DNA drop to undetectable levels in the blood, allowing patients to remain off continuous antiviral medications. Current standard treatments generally suppress viral replication but require lifelong administration. These findings mark a notable step forward in addressing chronic Hepatitis B, a condition that affects hundreds of millions of people globally.
- Approximately 20 percent of trial participants achieved a functional cure with the new therapy.
- A functional cure lowers Hepatitis B viral surface antigens and DNA to undetectable levels in the bloodstream.
- Existing standard care options control viral replication but typically require lifetime daily medication.
- Achieving a functional cure allows patients to safely discontinue ongoing antiviral treatments.
Based in Singapore, CNA (Channel News Asia) covers global developments with an Asian perspective, with correspondents based in major cities across Asia, including Kuala Lumpur, Jakarta, Bangkok, Tokyo, Seoul and Beijing, as well as in New York, Washington D.C. and London.
Official website: https://www.channelnewsasia.com/
Original video here.
This summary has been generated by AI.
